Multiple Myeloma Coverage from Every Angle

Recent News

Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma
Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy
AACR 2021: Is Novel IKZF1/3 Degrader Active Against Multiple Myeloma?
Isatuximab/Pomalidomide/Dexamethasone in Myeloma: Is Prescreening Patients for Biomarkers Warranted?
ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma
Expert European Panel Provides Clinical Practice Guidelines for Multiple Myeloma
Use of Generic Pomalidomide in India for Resistant Multiple Myeloma
Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial
FDA Approves Isatuximab-irfc Combination Therapy for Multiple Myeloma
FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma
Early Access Treatment Protocol of Daratumumab in European and Russian Patients With Resistant Myeloma
Combination Regimens for Transplant-Ineligible Myeloma: From the Canadian Myeloma Research Group
Avelumab Plus Hypofractionated Radiotherapy for Resistant Multiple Myeloma
Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma
Idecabtagene Vicleucel Under Study in Relapsed and Refractory Multiple Myeloma
Isolated Radiotherapy for Myeloma Lesions of the Cervical Spine: Case Report
Collaborative Initiative Offers Recommendations to Improve Diversity in Myeloma Trials
Long-Term Outcomes With Standard-of-Care Strategy in Multiple Myeloma
Melphalan Flufenamide Receives Accelerated Approval for Resistant Multiple Myeloma
Taking on Myeloma and Prostate Cancer: A Man Named Steele
TCT 2021: Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma?
Does a Patient’s Race Affect Access to IV Bisphosphonates in Multiple Myeloma?
Ixazomib Plus Standard Therapy for Myeloma: Outcomes in Routine Clinical Practice
Selinexor Triplet Under Study in Resistant Multiple Myeloma
Continued Trials for Iberdomide in Combination Therapy for Resistant Myeloma
Seeking the Right Dose of Immunoconjugate Combination in Resistant Myeloma
Corneal Changes With Antibody-Drug Conjugate in Myeloma: Mechanism Remains Unknown
Ixazomib Plus Standard Therapy in Transplant-Ineligible Patients With Myeloma
Cyclophosphamide Plus Weekly Carfilzomib and Dexamethasone in Resistant Myeloma
Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma
Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?
Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma
ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma
Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma
ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma
Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity
ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma
Are Carfilzomib-Based Regimens Safe and Effective for Frail Patients With Myeloma?
ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma
ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma
Myeloma and COVID-19: Dana-Farber and Quest Diagnostics Collaborate on IMPACT Study
Trends in Myeloma by Age: Treatment and Outcome Disparities Explored
ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma
ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma
ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma
Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.